retatrutide clinical trials duration Phase III study demonstrates 30% weight loss retatrutide clinical trial safety data

This stands in stark contrast to the US Fortress , where patent thickets may delay generic entry until 2031

Scientific studies have shown that this protection increases plasma glutathione levels threefold in just seven days

Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium

Less common but documented risks include pancreatitis, gallbladder disease, and acute kidney injury (often dehydration-driven from prolonged GI side effects)

Wegovy has been on the UK market since 2022, which means there are now several years of real-world safety data on top of the trial results